As metformin lowers plasma glucose levels without affecting insulin secretion, the addition of an agent such as vildagliptin which has a stimulatory action on insulin secretion is a suitable choice for combination therapy in patients with T2DM [13,25,37]. The gene discussed is INS; the disease is type 2 diabetes mellitus.